A detailed history of Quest Partners LLC transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Quest Partners LLC holds 19,748 shares of NTLA stock, worth $236,383. This represents 0.04% of its overall portfolio holdings.

Number of Shares
19,748
Previous 7,014 181.55%
Holding current value
$236,383
Previous $157 Million 158.53%
% of portfolio
0.04%
Previous 0.02%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

BUY
$19.72 - $27.36 $251,114 - $348,402
12,734 Added 181.55%
19,748 $406 Million
Q2 2024

Aug 06, 2024

SELL
$20.02 - $27.22 $55,915 - $76,025
-2,793 Reduced 28.48%
7,014 $157 Million
Q1 2024

May 09, 2024

SELL
$23.82 - $32.8 $14,506 - $19,975
-609 Reduced 5.85%
9,807 $270 Million
Q4 2023

Feb 09, 2024

BUY
$23.16 - $32.34 $241,234 - $336,853
10,416 New
10,416 $318 Million

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $910M
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Quest Partners LLC Portfolio

Follow Quest Partners LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Quest Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Quest Partners LLC with notifications on news.